HLA-G and cancer: It’s an exciting news released in Cancer Discovery “Gilead Buys into Tizona’s Anti-HLA-G Strategy” that an early clinical trial with human leukocyte antigen-G (HLA-G) inhibitor TTX-080 is being launched for advance solid cancer patients (NCT04485013) (2).